GEN-MKT-18-7897-A
Jan 24, 2019 | Blogs, Forensic | 0 comments
Anyone with children will remember that moment in the hospital when the nurse pricks the heel of your tiny new baby to squeeze out a few drops of blood onto a card. It’s an anxious moment but it’s over in a flash, and necessary to screen for rare but serious health conditions. This dried blood spot sampling technique was first introduced 55 years ago, and it has become the method of choice for newborn screening around the world.
But what does this have to do with forensic testing of novel psychoactive substances, after all, it is quite a leap to talk about newborn babies and then onto designer drugs? While dried blood spot sampling and analysis had to overcome hurdles in the early days, particularly due to low analytical throughput, there is a very good reason for its increasing attention in recent years in other applications.
It offers a faster, simpler alternative to serum/plasma or whole blood analysis in drug monitoring for toxicological analysis. In the tech note LC-MS/MS Screening of 64 New Psychoactive Substances Using Dried Blood Spots (as an Alternative to Whole Blood) we demonstrate the advantages, and here’s a rundown:
Sounds good, so what’s the catch? The small sample volume also means that the concentration of the target analyte is potentially quite low (e.g., less than 1 ng/L), requiring a highly sensitive and selective analysis method for detection and quantification. But in theory, there isn’t a catch if there is a solution, mass spectrometry. It is now the most common technique reported in literature for dried blood spot analysis and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) sets the benchmark.
In our method, researchers use the highly sensitive QTRAP® LC-MS/MS in Multiple Reaction Monitoring (MRM) mode using the Scheduled MRM™ Algorithm. The method is applied to authentic samples, and results are compared to a validated whole blood method used for routine analysis of NPS, yielding similar results. LOD was between 1 and 10 ng/ml, no interference from matrix compounds was observed, and the method was proven to be specific and selective for the analytes.
Fill out the form on your right to download the 2018 Forensics Compendium to see this method in its full glory, along with recent advancements developed by the forensics team and a view on where LC-MS/MS technology could take forensics in the future.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network